Radiation, mainstay of cancer treatment, begins a fade

Amaskusedinradiationtherapyshowslaserlinesfortargetingcancercellsinthebrain.AdobeEveryyear,doctorsge MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar




hotspot

author：focus    Page View：56136
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： How to make AI work for medicine
Next article： Walensky prepares to leave CDC — and Congress — behind